CL2018001133A1 - Faecalibacterium prausnitzii y desulfovibrio piger para uso en el tratamiento o prevención de la diabetes y enfermedades intestinales - Google Patents

Faecalibacterium prausnitzii y desulfovibrio piger para uso en el tratamiento o prevención de la diabetes y enfermedades intestinales

Info

Publication number
CL2018001133A1
CL2018001133A1 CL2018001133A CL2018001133A CL2018001133A1 CL 2018001133 A1 CL2018001133 A1 CL 2018001133A1 CL 2018001133 A CL2018001133 A CL 2018001133A CL 2018001133 A CL2018001133 A CL 2018001133A CL 2018001133 A1 CL2018001133 A1 CL 2018001133A1
Authority
CL
Chile
Prior art keywords
prevention
faecalibacterium prausnitzii
treatment
diabetes
intestinal diseases
Prior art date
Application number
CL2018001133A
Other languages
English (en)
Inventor
Muhammad-Tanweer Khan
Fredrik Bäckhed
Original Assignee
Metabogen Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabogen Ab filed Critical Metabogen Ab
Publication of CL2018001133A1 publication Critical patent/CL2018001133A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)

Abstract

<p>La presente invención se refiere, en general, al área de la medicina. Más específicamente, la invención se refiere al uso de bacterias probióticas sinérgicas como intervención para la salud. En particular, la presente invención proporciona una cepa de <em>Faecalibacterium prausnitzii </em>y una cepa bacteriana que tiene una o más de las características de: (i) ser productora de acetato, (ii) ser consumidora de lactato y (iii) tener la capacidad de ser un aceptor de electrones, para uso en el tratamiento o prevención de una enfermedad asociada con niveles reducidos de butirato o una enfermedad asociada con un número reducido o bajo de bacterias <em>Faecalibacterium prausnitzii</em>. </p>
CL2018001133A 2015-10-28 2018-04-27 Faecalibacterium prausnitzii y desulfovibrio piger para uso en el tratamiento o prevención de la diabetes y enfermedades intestinales CL2018001133A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1519088.7A GB201519088D0 (en) 2015-10-28 2015-10-28 The use of bacteria formulations

Publications (1)

Publication Number Publication Date
CL2018001133A1 true CL2018001133A1 (es) 2018-06-15

Family

ID=55130365

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001133A CL2018001133A1 (es) 2015-10-28 2018-04-27 Faecalibacterium prausnitzii y desulfovibrio piger para uso en el tratamiento o prevención de la diabetes y enfermedades intestinales

Country Status (17)

Country Link
US (2) US11260082B2 (es)
EP (1) EP3368053A1 (es)
JP (1) JP7018396B2 (es)
KR (2) KR20180070698A (es)
CN (2) CN115778986A (es)
AU (1) AU2016344770B2 (es)
BR (1) BR112018008312B1 (es)
CA (1) CA3002603A1 (es)
CL (1) CL2018001133A1 (es)
GB (1) GB201519088D0 (es)
IL (1) IL258881B2 (es)
MX (1) MX392357B (es)
RU (1) RU2754367C2 (es)
SG (1) SG11201803062XA (es)
UA (1) UA124926C2 (es)
WO (1) WO2017072278A1 (es)
ZA (1) ZA201802585B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11959125B2 (en) * 2016-09-15 2024-04-16 Sun Genomics, Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
BR112019025948A2 (pt) 2017-06-16 2020-06-30 Biofermin Pharmaceutical Co., Ltd. agente para prevenir ou tratar doenças e/ou inflamação associadas à gordura
JP2020530493A (ja) * 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド． 腸内の抗生物質耐性菌を除菌するための組成物及び方法
US11491192B2 (en) 2018-01-09 2022-11-08 The Cleveland Clinic Foundation Treatment and prevention of pathogenic bacterial overgrowth using butyrate-producing bacteria
US20210393737A1 (en) * 2018-09-25 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of mam polypeptides for the treatment of obesity and obesity-related disorders
CN110878349A (zh) * 2019-12-06 2020-03-13 深圳谱元科技有限公司 终末期肾病生物标志物及其应用
EP3858363A1 (en) * 2020-01-28 2021-08-04 Institut national de recherche pour l'agriculture, l'alimentation et l'environnement Composition for treating intestinal or pulmonary diseases
ES3066795T3 (en) 2020-02-28 2026-05-18 Stichting Amsterdam UMC Intervention strategy for prevention or treatment of diabetes mellitus, autoimmune disease, inflammatory disease or cardiovascular disease
NL2025020B1 (en) * 2020-02-28 2021-10-14 Acad Medisch Ct Intervention strategy for prevention or treatment of autoimmune diseases
KR102169794B1 (ko) * 2020-06-24 2020-10-27 주식회사 엔테로바이옴 신규한 피칼리박테리움 프로스니치 균주 eb-fpdk11 및 그의 용도
KR102169795B1 (ko) * 2020-06-24 2020-10-27 주식회사 엔테로바이옴 신규한 피칼리박테리움 프로스니치 eb-fpdk9 균주 및 그의 용도
KR102185828B1 (ko) * 2020-08-26 2020-12-03 주식회사 엔테로바이옴 피칼리박테리움 프로스니치 균주를 포함하는 아토피성 질환 예방 또는 치료용 약학적 조성물
KR102245415B1 (ko) * 2020-12-14 2021-04-29 주식회사 엔테로바이옴 피칼리박테리움 프로스니치 균주 배양 배지 조성물
EP4333644A1 (en) * 2021-05-06 2024-03-13 Société des Produits Nestlé S.A. Compositions and methods using at least one of inositol, erythritol or sorbitol to enhance growth of faecalibacterium prausnitzii
CN113201575A (zh) * 2021-05-11 2021-08-03 西安医学院第一附属医院 基于普氏粪杆菌对动物肾脏炎症反应变化影响的研究方法
CN113797232B (zh) * 2021-10-28 2023-05-26 南昌大学 具有缓解胰岛素抵抗功能的组合物及其应用
CN114304380A (zh) * 2022-01-13 2022-04-12 合肥河川生物医药科技有限公司 普拉梭菌在猪鸡上的应用
CN117384867B (zh) * 2022-09-16 2024-06-07 北京普译生物科技有限公司 一种经修饰的Cas3移位酶及其应用
CN117016672B (zh) * 2023-08-29 2026-03-27 天晴干细胞股份有限公司 一种诱导2型糖尿病饲料及其在建立2型糖尿病动物模型中的应用
CN118845848B (zh) * 2024-07-01 2025-10-17 温州大学 普氏粪杆菌dsm 17677在制备防治猪流行性腹泻病毒感染产品中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20100048595A1 (en) * 2005-03-23 2010-02-25 Washington University In St. Louis Use of archaea to modulate the nutrient harvesting functions of the gastrointestinal microbiota
JP2007189947A (ja) * 2006-01-19 2007-08-02 Gifu Univ 硫化水素産生菌抑制剤及び硫化水素産生菌抑制方法
BR112014010660A2 (pt) 2011-11-04 2017-05-09 Gen Mills Inc métodos e composições para modular bactéria gastrointestinal
US9314494B2 (en) * 2012-05-25 2016-04-19 The United States Of America, As Represented By The Secretary Of Agriculture Cranberry xyloglucan oligosaccharide composition
MX2015006491A (es) * 2012-11-23 2015-12-03 Seres Health Inc Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas.
KR20150134356A (ko) * 2013-03-05 2015-12-01 리엑스유니버시테이트 그로닝겐 염증을 억제하기 위한 페칼리 박테리움 프라우스니치이 htf-f (dsm 26943)의 용도
US9907755B2 (en) * 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
BR112015023089A2 (pt) * 2013-03-15 2017-11-21 Amyris Inc célula hospedeira, método para produzir um isoprenoide, e método para aumentar a produção de acetil-coa ou um composto derivado de acetil-coa
US20150246081A1 (en) * 2014-03-03 2015-09-03 Shayne Kenneth Morris Probiotics with methods for growth and use separately and in combination
AU2018318756B2 (en) * 2017-08-14 2021-12-02 Macrogen Inc. Disease-associated microbiome characterization process

Also Published As

Publication number Publication date
RU2021113597A3 (es) 2021-10-27
IL258881B1 (en) 2023-07-01
RU2021113597A (ru) 2021-06-25
MX392357B (es) 2025-03-24
JP2018532779A (ja) 2018-11-08
KR102371868B1 (ko) 2022-03-07
RU2018119309A3 (es) 2020-03-26
RU2754367C2 (ru) 2021-09-01
AU2016344770A1 (en) 2018-05-10
BR112018008312B1 (pt) 2023-11-07
WO2017072278A1 (en) 2017-05-04
CN115778986A (zh) 2023-03-14
BR112018008312A2 (pt) 2018-10-30
SG11201803062XA (en) 2018-05-30
GB201519088D0 (en) 2015-12-09
AU2016344770B2 (en) 2023-07-13
AU2016344770A2 (en) 2018-05-17
US20200405777A1 (en) 2020-12-31
WO2017072278A8 (en) 2017-12-07
US20220133814A1 (en) 2022-05-05
RU2018119309A (ru) 2019-11-28
JP7018396B2 (ja) 2022-02-10
ZA201802585B (en) 2019-07-31
IL258881A (en) 2018-06-28
US12318412B2 (en) 2025-06-03
US11260082B2 (en) 2022-03-01
CN108367030A (zh) 2018-08-03
EP3368053A1 (en) 2018-09-05
CA3002603A1 (en) 2017-05-04
UA124926C2 (uk) 2021-12-15
HK1257739A1 (zh) 2019-10-25
CN108367030B (zh) 2022-12-27
MX2018005261A (es) 2019-07-04
IL258881B2 (en) 2023-11-01
KR20210000758A (ko) 2021-01-05
KR20180070698A (ko) 2018-06-26

Similar Documents

Publication Publication Date Title
MX2018005261A (es) Faecalibacterium prausnitzii y desulfovibrio piger para usarse en el tratamiento o prevencion de diabetes y enfermedades intestinales.
de Almada et al. Paraprobiotics: Evidences on their ability to modify biological responses, inactivation methods and perspectives on their application in foods
MX2019014045A (es) Composiciones y metodos.
ES2408279R1 (es) Bacteria acido lactica probiotica
MX2019009132A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
AR106768A1 (es) Composiciones que comprenden cepas bacterianas
EA201792547A1 (ru) Популяции бактерий для стимуляции состояния здоровья
GB2551642A (en) Methods and compositions relating to microbial treatment and diagnosis of dis-orders
BR112018003745A2 (pt) composições que compreendem um composto de urolitina
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112014030434A2 (pt) método não terapêutico; uso de uma proteína; composição nutricional; e uso da composição nutricional
UA107711C2 (en) Use of lactobacilli inhibiting gas producing coliform bacteria isolated from infants affected by colic
BR112018003780A2 (pt) composições que compreendem um composto de urolitina
MX353230B (es) Un bacteriofago para biocontrol de salmonella y en la preparacion o procesamiento de alimentos.
BR112017014649A2 (pt) ?isolado intestinal humano, e, composição?
BR112017023636A2 (pt) suplemento dietético
EA201991301A1 (ru) Урогенитальная композиция для медицинского устройства на основе подходящих биохимических композиций для стабилизации кислотности и редокс-состояния вагинальной жидкости
MX2022011742A (es) Composicion nutritiva para el entorno gastrointestinal para proporcionar microbioma y perfil metabolico mejorados.
MX2017016283A (es) Lactobacillus paracasei para la produccion de acido linoleico conjugado, preparaciones nutricionales y farmaceuticas que lo contienen y sus usos.
CR20150217A (es) Inhibidores de histona demetilasas
PE20141452A1 (es) Cepas de salmonella gallinarum modificadas avirulentas y composiciones farmaceuticas que las usan
IN2014DN06737A (es)
BR112017011850A2 (pt) métodos e reagentes para detectar neisseria gonorrhoeae e seus determinantes de resistência antimicrobiana
CL2016000746A1 (es) Un método para producir un l-aminoácido usando una bacteria de la familia de las enterobacteriaceae teniendo atenuada la expresión de un gen que codifica un transportador de fosfato
MX383993B (es) Cepa de aspergillus niger f22 que tiene actividad nematicida contra nematodos parásitos de las plantas, y uso de la misma.